Non-cystic Fibrosis Bronchiectasis (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by a permanent dilation of bronchi, retention of mucus, and ciliary clearance impairment. Clinical features include chronic daily sputum, cough, shortness of breath, and recurrent respiratory infections, with consequent increased morbidity and worsened quality of life. One of the cornerstones in the management of bronchiectasis is the identification and treatment of underlying causes.
DelveInsight’s ‘Non-cystic Fibrosis Bronchiectasis Pipeline Insights’ report offers exhaustive coverage of the emerging therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents.
Some of the important takeaways from the Non-cystic Fibrosis Bronchiectasis Pipeline report:
Request for free Sample Report: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
NCFB Symptoms
The symptoms and clinical course of NCFB are variable. Some patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily.
Non-cystic Fibrosis Bronchiectasis Causes
The most common cause of NCFB in the literature is post-infectious. This is not a well-defined entity, but the usual context appears to be one acute infectious episode that is thought to result in bronchiectasis. A possible mechanism for post-infectious NCFB is a significant infection in early childhood which causes structural damage to the developing lung, allowing perpetual bacterial infection. Over time, persistent infection may then result in bronchiectasis.
Non-cystic Fibrosis Bronchiectasis Companies are:
DelveInsight’s NCFB Report covers around 5+ products under different phases of clinical development like:
Non-cystic Fibrosis Bronchiectasis Therapies are:
Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report
Coverage: Global
Key Players: Santhera Pharmaceuticals, Novartis, InsMed, Zambon, Chiesi Farmaceutici, among others.
Key Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies: Lonodelestat, Tobramycin dry-powder inhalation, INS-1007, Colistimethate sodium, CHF 6333, among others.
Table of Contents
1
Report Introduction
2
Executive Summary
3
Non-Cystic Fibrosis Bronchiectasis Disease Overview
4
NCFB Pipeline Therapeutics Comparative Analysis
5
Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment
6
Non-Cystic Fibrosis Bronchiectasis – DelveInsight’s Analytical Perspective
7
In-depth Commercial Non-Cystic Fibrosis Bronchiectasis Assessment
8
Non-Cystic Fibrosis Bronchiectasis Collaboration Deals
9
Late Stage Non-Cystic Fibrosis Bronchiectasis Products (Phase III)
10
Mid-Stage Non-Cystic Fibrosis Bronchiectasis Products (Phase II)
11
Early Stage Non-Cystic Fibrosis Bronchiectasis Products (Phase I)
12
Pre-clinical and Discovery Stage NCFB Products
13
Inactive Non-Cystic Fibrosis Bronchiectasis Pipeline Products
14
Key Non-Cystic Fibrosis Bronchiectasis Products
15
Unmet Needs
16
NCFB Market Drivers and Barriers
17
Future Perspectives and Conclusion
18
Analyst Views
19
Key Non-Cystic Fibrosis Bronchiectasis Companies
20
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight